Manfidokimab vs Telikibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline

Manfidokimab

Developed by Akeso

Phase 3 in Atopic Dermatitismonoclonal antibody
Partial signal

NCT06383468 · Phase 3 · status unknown

This Phase 3 trial randomly assigned adults with moderate-to-severe atopic dermatitis to manfidokimab (AK120) or placebo, both delivered by subcutaneous injection, under quadruple-blind conditions, with the proportion of patients achieving EASI-75 (75% improvement in eczema severity) at week 16 as the primary endpoint. No results have been posted, so this remains a well-designed, adequately sized, blinded, placebo-controlled trial whose findings are not yet known.

Next expected readout: July 2027 · NCT06767540 (registry estimate)

No aligned efficacy figure on record for this race.

Telikibart

Developed by Genrix Bio

Phase 3 in Atopic Dermatitismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointManfidokimabTelikibart
EASI-75—Trial running · NCT06767540—Not reported
IGA 0/1 with 2-point improvement—Trial running · NCT06767540—Not reported
EASI-90—Trial running · NCT06767540—Not reported
EASI, % change—Trial running · NCT06767540—Not reported

EASI-75

Manfidokimab
—Trial running · NCT06767540
Telikibart
—Not reported

IGA 0/1 with 2-point improvement

Manfidokimab
—Trial running · NCT06767540
Telikibart
—Not reported

EASI-90

Manfidokimab
—Trial running · NCT06767540
Telikibart
—Not reported

EASI, % change

Manfidokimab
—Trial running · NCT06767540
Telikibart
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Manfidokimab: no structured comparison results are available for Atopic Dermatitis.

Telikibart: no structured comparison results are available for Atopic Dermatitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Manfidokimab's landscape · Telikibart's landscape